×
Kintara Therapeutics Share Holder Equity 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kintara Therapeutics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
View More
Kintara Therapeutics Share Holder Equity 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kintara Therapeutics share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.2B
Vertex Pharmaceuticals (VRTX)
$123.4B
Gilead Sciences (GILD)
$107.4B
Regeneron Pharmaceuticals (REGN)
$106.8B
Bristol Myers Squibb (BMY)
$105.7B
CSL (CSLLY)
$97.7B
GSK (GSK)
$79.1B
Alnylam Pharmaceuticals (ALNY)
$37.5B
Argenex SE (ARGX)
$33.5B
Biogen (BIIB)
$26.9B
BioNTech SE (BNTX)
$26.5B
Illumina (ILMN)
$23.1B
BeiGene (BGNE)
$21.4B
Moderna (MRNA)
$20.7B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.3B
Vaxcyte (PCVX)
$12.9B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.4B
Sarepta Therapeutics (SRPT)
$12.1B
Bio-Techne Corp (TECH)
$11.2B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.4B
Exelixis (EXEL)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Revolution Medicines (RVMD)
$8B
Legend Biotech (LEGN)
$7.9B